confirmed the diagnosis of donovanosis. A 6 week course of doxycycline 100 mg twice daily was commenced, and the patient made a full recovery.

In view of the increased transmissibility of HIV in association with ulcerating genital infections, an effective and acceptable oral agent is required for the treatment of donovanosis. Few well designed controlled trials have addressed this problem. Effective treatment and prevention of ulcerating genital disease is important in the control of the spread of HIV. Clinicians investigating patients from tropical countries should be aware that trimethoprim and co-trimoxazole do not always eradicate donovanosis.

KARL BIRTHSTILLE
JAMES GREG
Department of Medical Microbiology,
St George’s Hospital Medical School,
London SW17 0RE

PHILIP HAY
Department of Genito-urinary Medicine,
St George’s Hospital Medical School,
London SW17 0RE


Accepted for publication 12 February 1997

Perforation of hard palate in lues maligna associated with HIV infection

Unusual oral and skin manifestations of infectious diseases may be observed in patients with HIV infection. The case is quoted as a guide to the clinician. Destructive bone diseases such as osteitis pubis and osteomyelitis are well known complications of congenital and tertiary syphilis; they are rare complications of early acquired syphilis. We report a case of perforation of hard palate in lues maligna associated with HIV infection. A 30 year old promiscuous male presented with a solitary genital ulcer and recurrent erythematous nodules and ulcers over the

Figure 1 Ulcers over the toes and feet nodules over the dorsum of feet.

Figure 2 Perforation of hard palate.


Accepted for publication 12 February 1997

Sharing prescribing of continuous aciclovir treatment: effects of a new policy and general practitioner responses

Recent guidelines on the care of patients with genital herpes1 include reference to improved communication between local genitourinary medicine clinics and general practitioners. This reinforces anecdotal reports that in some areas of the UK general practitioners and genitourinary medicine clinics were satisfactorily collaborating in the management of patients requesting continuous treatment with aciclovir. In early 1996 the national reduction in HIV funding by 7-7% and the lack of designated additional funding for new antiviral drugs have resulted in extreme pressure on the drug budget within the directorate of HIV/GU medicine at the Chelsea and Westminster Hospital and prompted us to examine ways of extending collaboration with general practitioners with the secondary gain of achieving an overall reduction in our drugs budget. After discussion within the unit and with purchasers we attempted to reduce our purine deficit by restricting hospital prescribed therapies to treatments for HIV infection, and acute and new presentations of STDs. With the intention of preserving patient choice concerning confidentiality, however, we asked for our patients' specific consent to write to their general practitioners to request them to share responsibilities in the prescribing of continuous aciclovir for the prevention of recurrent genital herpes. This policy took effect from April 1996, and during the following 5 months we approached 71 patients who were receiving regular prescriptions for continuous aciclovir to prevent recurrences of culture proved genital herpes from the genitourinary medicine clinic. Eight patients refused to have their herpes diagnosis and prescription needs disclosed to their general practitioners.

Correspondence to: Dr C Balachandran.
all as a result of concerns about confidentiality. All these patients have documented their decision in writing. High-risk patients offered to make a contribution to the costs if it was possible to continue on hospital prescriptions, but there is at present no logistical method for achieving this. Of the 63 general practitioners contacted, four refused to enter the recommended aciclovir treatment, predominantly citing the grounds of costs or not wishing to accept responsibility for the care. Overall, 59 patients were successfully referred to their general practitioners who continued to prescribe the recommended dosages of aciclovir. This did not reduce the frequency of visits to the genitourinary medicine clinic as continued monitoring of the therapy, ongoing support, and counselling and discussion on when to cease therapy were carried out in the clinic according to our protocol.

Our experience suggests that the overwhelming majority of patients are prepared to give permission for the involvement of the general practitioner in the management of their genital herpes and that the majority of general practitioners are pleased to cooperate clinically in this management. All newly diagnosed patients with genital herpes are now being directly asked for their permission to involve their general practitioner in their care and we will continue to audit our experience of the uptake of this. A small proportion of patients continue on hospital prescriptions because of their concern about confidentiality.

Barbara Vona

Accepted for publication 17 February 1997

Hypospadias associated with the use of high dose megestrol acetate in an HIV infected woman

Megestrol acetate has been used to stimulate appetite and promote weight gain in patients with acquired immunodeficiency syndrome (AIDS) related cachexia and wasting. We report a case of hypospadias associated with the use of high dose megestrol acetate during the first trimester of pregnancy.

Hypospadias is a congenital malformation, in which the urethral meatus forms proximal to its normal position, resulting from incomplete fusion of the urethral groove during fetal development. The normal process of fusion is brought about by androgens from the fetal testes during the fourth to eighth week of gestation.1 Hypospadias is a relatively common abnormality, with a prevalence ranging from 1 in 300 to 1 in 1000 male births in the general population.2 Synoptic progestogens have been suggested as possible low risk teratogens for a range of congenital abnormalities. While the association of hypospadias with the use of standard doses of synthetic progestogens during pregnancy has been described,3 there have been no reports to date of birth defects associated with the use of high dose megestrol acetate.

Thirty women with human immunodeficiency virus (HIV) who were more than 10% weight loss, were enrolled in a study of weight gain using an oral suspension of megestrol acetate. Patients were randomised to receive either 400 mg or 800 mg of megestrol acetate per day for 24 weeks. A 28 year old HIV positive female participant was included in the study with the following chronology of events. At enrolment, she had had surgery 2 months earlier for an ectopic pregnancy with irregular menses, and her initial serum pregnancy test was negative. She could be discerned regarding the necessity of using barrier method contraception. She started taking megestrol acetate but failed to attend for follow up clinic visits. Subsequently, pregnancy testing and ultrasonography demonstrated that she was 17 (SD 2) weeks pregnant. It was determined retrospectively that she had taken megestrol acetate, 400 mg per day, for 18 days from the 4th to the 7th week of pregnancy (by ultrasound dates). Her only medication was zidovudine, 600 mg per day. At 38 weeks gestation, she delivered by repeat caesarean section a live male infant, with normal Apgar scores, weighing 2633 g, with second degree hypospadias. The boy, now 7 months old and HIV negative, will require continuous follow up.

High doses of megestrol acetate in the first trimester of pregnancy may increase the risk of hypospadias. This warning appears in the drug manufacturer's prescribing information. Caution needs to be exercised in prescribing megestrol acetate to HIV infected women with reproductive potential. Repeated counselling of patients on the use of adequate contraception and education of staff and patients regarding potential teratogenic effects of megestrol acetate should be stressed.

David J FARRAR
Reenee AROMIN
Susan Cu Uvin
Timothy P Flanagan
Maria D Mileno
Department of Medicine, The Miriam Hospital, Brown University School of Medicine, Providence, Rhode Island, USA

Correspondence to: Dr M D Mileno, Immunology Center, The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906, USA.


Accepted for publication 3 March 1997

Lymphoedema of the genitalia secondary to skin tuberculosis: report of three cases

Lymphoedema of the genitalia due to lymphatic obstruction is generally caused by filariasis, at times by neoplastic changes, and rarely, by lymphogranuloma venerum or donovanosis. We report its unusual occurrence in a case of scrofuloderma and one with lupus vulgaris.

Case reports

Case report 1

A 25 year old woman with a 15 year history of recurrent swellings in the neck and groin daily was treated with indigeneous relief. Later she had swelling of the vulva which brought her to the hospital. Examination revealed irregular scarring and few intermittently discharging sinus ever the submandibular and cervical areas. Multiple abscesses and sinus were seen, affecting the inguinal lymph nodes at both sides. The soft and swollen vulva showed vesicles, some of which had eroded. Systemic examination revealed no abnormality.

In investigations revealed a haemoglobin of 10 g/dl, white cell count 10·4 × 10⁹/l, differen-
tial—polymorphs 50, lymphocytes 34, eosinophils 26, erythrocyte sedimentation rate 40 mm in the first hour. X rays of the chest and pelvis disclosed no abnormality. Biopsy from an active lesion was sent for histopathology and culture in the Lowenstein-Jensen medium. The former revealed a thinned and ulcerated epithelium. In the dermis an acute inflammatory infiltrate was seen around a necrotic area. The deeper dermis showed few tuberculoid structures with epitheloid and occasional Langhans giant cells surrounded by lymphocytes. No acid fast bacilli were demonstrable in Ziehl-Neelsen stained sections. Mycobacterium tuberculosis was isolated on culture. Oral antitubercular treatment (ATT) comprising rifampicin 450 mg/day, 300 mg/day and pyrazinamide 750 mg twice daily was started. Significant swelling was seen after 2 months; pyrazinamide was stopped and the first two were continued. After 3 months the vulval swelling had decreased. She was advised to continue regular treatment but did not report to the hospital again.

Case report 2

A 30 year old begger had occasionally discharged inguinal lesions of 10 years' duration. They had started on the right side and spread over a period of time. There was no history of pulmonary tuberculosis. He had later noticed an increase in scrotal size. Examination revealed fluctuant areas and partially healed sinus over the inguinal lymph nodes of both sides. Healed areas were connected by thick scars extending into the suprapubic area. There was scanty to moderate discharge from the sinuses. The scrotum and penis skin were thinned and oedematous (fig). The perianal region appeared normal.

Routine blood and urinalysis, and X rays of the chest and pelvis area were within nor-